KR20210008847A - 카나키누맙의 용도 - Google Patents

카나키누맙의 용도 Download PDF

Info

Publication number
KR20210008847A
KR20210008847A KR1020207035003A KR20207035003A KR20210008847A KR 20210008847 A KR20210008847 A KR 20210008847A KR 1020207035003 A KR1020207035003 A KR 1020207035003A KR 20207035003 A KR20207035003 A KR 20207035003A KR 20210008847 A KR20210008847 A KR 20210008847A
Authority
KR
South Korea
Prior art keywords
kanakinumab
patient
less
administration
hscrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207035003A
Other languages
English (en)
Korean (ko)
Inventor
마티아스 시커
린다 민데홀름
젠스 프래스트가드
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20210008847A publication Critical patent/KR20210008847A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
KR1020207035003A 2018-05-09 2018-08-24 카나키누맙의 용도 Withdrawn KR20210008847A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669071P 2018-05-09 2018-05-09
US62/669,071 2018-05-09
PCT/IB2018/056455 WO2019215484A1 (en) 2018-05-09 2018-08-24 Use of canakinumab

Publications (1)

Publication Number Publication Date
KR20210008847A true KR20210008847A (ko) 2021-01-25

Family

ID=63638190

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035003A Withdrawn KR20210008847A (ko) 2018-05-09 2018-08-24 카나키누맙의 용도

Country Status (12)

Country Link
US (1) US20210371511A1 (cg-RX-API-DMAC7.html)
EP (1) EP3790576A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021523894A (cg-RX-API-DMAC7.html)
KR (1) KR20210008847A (cg-RX-API-DMAC7.html)
CN (2) CN119746057A (cg-RX-API-DMAC7.html)
AU (1) AU2018422406A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020022576A2 (cg-RX-API-DMAC7.html)
CA (1) CA3098277A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002881A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020011909A (cg-RX-API-DMAC7.html)
TW (1) TW201946652A (cg-RX-API-DMAC7.html)
WO (1) WO2019215484A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2963828A1 (en) 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
AU2011325134B2 (en) * 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
WO2013049278A1 (en) 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES
TW201536320A (zh) * 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018234879A1 (en) * 2017-06-22 2018-12-27 Novartis Ag USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
CN107723310B (zh) * 2017-10-19 2024-01-09 北京睿诚海汇健康科技有限公司 植物作为宿主在表达卡那抗体中的应用

Also Published As

Publication number Publication date
TW201946652A (zh) 2019-12-16
WO2019215484A1 (en) 2019-11-14
BR112020022576A2 (pt) 2021-02-09
CN112584857A (zh) 2021-03-30
CN119746057A (zh) 2025-04-04
US20210371511A1 (en) 2021-12-02
JP2021523894A (ja) 2021-09-09
CL2020002881A1 (es) 2021-05-14
JP2023071904A (ja) 2023-05-23
EP3790576A1 (en) 2021-03-17
CA3098277A1 (en) 2019-11-14
MX2020011909A (es) 2021-01-29
JP7713983B2 (ja) 2025-07-28
AU2018422406A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
JP6515168B2 (ja) Il−17アンタゴニストを用いて関節リウマチを治療する方法
KR20150018533A (ko) 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
BR112021010789A2 (pt) Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
RU2697383C2 (ru) Применение антагонистов il-17 для торможения прогрессирования структурных повреждений у пациентов с псориатическим артритом
JP2021503476A (ja) Il−17アンタゴニストを用いて化膿性汗腺炎を治療すること
US20220340668A1 (en) Treatment of liver disease or disorder comprising actrii receptor antagonists
AU2014360704A1 (en) Compositions and methods for treating osteoarthritis
JP2023138982A (ja) インターロイキン-17(il-17)アンタゴニストを使用して腱障害を治療する方法
JP7713983B2 (ja) カナキヌマブの使用
JP2024517739A (ja) 血管炎症、アテローム性動脈硬化症及び関連する障害を治療する方法
WO2025072725A1 (en) Methods for the treatment of cardiovascular disease
CN119546340A (zh) 使用白细胞介素-17(il-17)拮抗剂选择性治疗肌腱病的方法
JP2017528445A (ja) 肝細胞癌の抗vegfr2抗体治療
WO2020039401A1 (en) Treatment comprising il-1βeta binding antibodies and combinations thereof
TW202502379A (zh) 抗il-36r抗體用於治療化膿性汗腺炎(hs)之用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210823

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20211110

WITB Written withdrawal of application